Aethlon Medical

There is no commercial pricing history. The theoretical ability to price for a life‑saving adjunct is constrained by the need for clear clinical benefit and payer coverage decisions. Until randomized data demonstrate outcome improvements on top of standard therapies, realized pricing power is minimal.

Comparable categories have faced intense scrutiny and mixed adoption even with EUAs, which were rolled back post‑emergency.